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ReportsPhase I Trial of Recombinant
Human Nerve Growth Factor
for Neurotrophic KeratitisNeurotrophic keratitis/keratopathy (NK), a rare degenerative
corneal disease, lacks effective pharmacologic therapies.1 Because
NK pathology involves trigeminal nerve damage and loss of
corneal innervation, nerve growth factor (NGF) is surmised to
promote healing of NK.2 Preliminary studies with murine NGF
demonstrated efficacy for treating corneal neurotrophic ulcers;3
however, the complex tertiary structure of NGF has complicated
the production of recombinant human NGF (rhNGF) suitable for
clinical development. To this end, we developed an Escherichia
coliederived rhNGF formulation that demonstrated to be well
tolerated and safe for topical ophthalmic use in a phase I study
in healthy volunteers.4 We report phase I results of topical
rhNGF for patients with moderate-to-severe NK.
NGF0212/REPARO (Latin, “repair”) was a phase I/II random-
ized, double-masked, multicenter, vehicle-controlled, parallel group
study (ClinicalTrials.gov identifier NCT01756456) that evaluated
the safety and efficacy of rhNGF eye drops (10 or 20 mg/ml,
6 drops/day for 8 weeks) in patients with moderate (stage 2) or
severe (stage 3) NK.
Patients aged 18 years with stage 2 or 3 NK were enrolled
according to published diagnostic criteria and inclusion/exclusion
criteria described in the REPARO phase II report.5 Table 1
summarizes patient demographics, baseline characteristics, and
prior NK treatments.
Eighteen phase I patients (2 cohorts of 9 consecutively enrolled
patients each) with stage 2 or 3 NK gave informed consent and were
randomized 7:2 to rhNGF 10 mg/ml versus vehicle (cohort A) or
rhNGF 20 mg/ml versus vehicle (cohort B). Sample size was based
on clinical feasibility (i.e., no formal power calculation was per-
formed), because phase I aimed primarily to assess the safety and
systemic absorption of topical rhNGF to support proceeding with
phase II, which was conducted, analyzed, and reported separately.5
Patients, investigators, and site/sponsor staff were masked to
primary randomized treatment. Indistinguishable treatment kits
were randomly assigned by Statistical Analysis System pro-
grammers. A clinical research organization maintained the masked
database. No formal statistical testing was applied to phase I data.
The study obtained institutional review board and independent
ethics committee approval (detailed in the phase II report5) and
complied with the Declaration of Helsinki, Code of Federal
Regulations, and Good Laboratory/Clinical Practice guidelines.
Figure S1 (available at www.aaojournal.org) depicts overall
study design and patient disposition, including reasons for
withdrawal. The study included an 8-week controlled treatment
period and a 48- or 56-week follow-up (duration determined by
treatment allocation and corneal healing status during controlled
treatment). In the event of treatment failure during the 8-week
controlled treatment period (predefined as failure to achieve
corneal healing, recurrence of NK after healing, or deterioration as
described in the phase II report5), vehicle-treated patients wereeligible to receive 8 weeks of uncontrolled rhNGF treatment
(cohort A: 10 mg/ml; cohort B: 20 mg/ml) before continuing follow-
up (total follow-up: 56 weeks). However, no phase I patients
entered the 56-week follow-up period.
The primary safety variable was incidence of adverse events
(AEs), defined per Good Clinical Practice guidelines as any un-
toward medical occurrences in patients who received study treat-
ment, regardless of causal or temporal association. Other safety
parameters included visual analogue scale for ocular tolerability
(described in the phase II report5), best-corrected distance visual
acuity measured in Early Treatment Diabetic Retinopathy Study
letters, intraocular pressure, dilated fundus ophthalmoscopy, vital
signs, hematology, and clinical chemistry.
Table 1 summarizes treatment-related AEs (TAEs), defined as
AEs recorded by the investigator as having possible, probable, or
highly probable relationships to study treatment, during controlled
treatment. Eye pain and headache were the most frequently re-
ported TAEs during controlled treatment, each occurring in 2 pa-
tients (28.6%) in the rhNGF 20 mg/ml group. Treatment-related
AEs reported during controlled treatment occurred in 1 of 18 pa-
tients each. No TAEs were reported during the 48-week follow-up.
No deaths occurred during controlled treatment or follow-up, nor
were there any notable trends or clinically significant differences
over time or between treatment groups in laboratory parameters,
vital signs, or other ocular safety assessments.
Pharmacokinetics (PK) profiling was performed as described
previously.4 As shown in Figure S2 (available at
www.aaojournal.org), only 2 patients had detectable serum NGF
at any time point. Of note, the patient in the rhNGF 10 mg/ml
group had only 1 positive NGF measurement during the study,
and the patient in the rhNGF 20 mg/ml group had detectable
serum NGF levels at all time points, even before initiating study
treatment. Taken together, the PK results suggest individual
fluctuations of endogenous NGF independent of study treatment.
Although the phase I study was not designed or powered for
efficacy outcomes, corneal healing (<0.5 mm fluorescein staining
in the lesion area) was assessed in clinical pictures by central
readers (masked to treatment assignment and duration) at week 4
(primary end point) and week 8 (key secondary end point). At
week 4, based on postbaseline last-observation-carried-forward
analysis, corneal healing was achieved by 1 of 4 patients
(25.0%) receiving vehicle, 3 of 7 patients (42.9%) receiving
rhNGF 10 mg/ml, and 3 of 7 patients (42.9%) receiving rhNGF 20
mg/ml. Of patients with responses available at week 8, corneal
healing was achieved by 1 of 2 patients (50%) receiving vehicle, 4
of 6 patients (66.7%) receiving rhNGF 10 mg/ml, and 6 of 7 pa-
tients (85.7%) receiving rhNGF 20 mg/ml. No phase I patients
discontinued because of a lack of efficacy or inadequate control of
NK. Before week 8, no patients in any treatment group experienced
deterioration. At week 8, 1 patient who received rhNGF 20 mg/ml
experienced a decrease in best-corrected distance visual acuity
score of >5 Early Treatment Diabetic Retinopathy Study letters.
The REPARO phase I study demonstrated that topical
ophthalmic rhNGF (10 or 20 mg/ml), administered 6 drops/day for1
Table 1. Patient Demographics, Baseline Characteristics, Prior Treatments, and Treatment-Related Adverse Events*
Characteristics
Recombinant Human Nerve Growth Factor
10 mg/ml (N¼7) 20 mg/ml (N¼7) Vehicle (N[4)
Age (yrs)
Mean (SD) 61.7 (21.47) 52.0 (17.24) 64.3 (24.06)
Median (min, max) 67.0 (29, 80) 55.0 (24, 71) 68.5 (34, 86)
Female, n (%) 3 (42.9) 4 (57.1) 2 (50.0)
Ethnicity, n (%)
Hispanic, Latino, or Spanish 1 (14.3) 0 0
N/A 0 1 (14.3) 0
Race, n (%)
White 7 (100.0) 6 (85.7) 4 (100.0)
N/A 0 1 (14.3) 0
Primary NK diagnosis, n (%)
Stage 2 3 (42.9) 5 (71.4) 2 (50.0)
Stage 3 4 (57.1) 2 (28.6) 2 (50.0)
Underlying cause, n (%)
Diabetes mellitus 1 (14.3) 2 (28.6) 1 (25.0)
Dry eye disease 1 (14.3) 0 0
Herpetic eye diseasey 1 (14.3) 2 (28.6) 2 (50.0)
Neurosurgical procedure (medulloblastoma excision) 2 (28.6) 1 (14.3) 0
Ocular surgery or procedure
Cataract surgery/scleral buckle/vitrectomy 1 (14.3) 1 (14.3) 0
Keratoplasty 1 (14.3) 0 0
LASIK 0 1 (14.3) 0
Stroke 0 0 1 (25.0)
Prior treatments, n (%)z
Artificial tears/gels/ointments 1 (14.3) 6 (85.7) 3 (75.0)
Preservative-free artificial tears/gels/ointments 4 (57.1) 4 (57.1) 2 (50.0)
Topical antibiotics 4 (57.1) 4 (57.1) 3 (75.0)
Therapeutic contact lens 2 (28.6) 1 (14.3) 1 (25.0)
Autologous serum eye drops 1 (14.3) 2 (28.6) 1 (25.0)
Other 0 2 (28.6) 0
TAEs (Controlled Treatment Period)
No. of
Events Reported
No. of
Patients (%)
No. of
Events Reported
No. of
Patients (%)
No. of
Events Reported
No. of
Patients (%)
Body system
MedDRA preferred term
Any AE 4 1 (14.3) 12 3 (42.9) 1 1 (25.0)
Eye disorders 3 1 (14.3) 5 3 (42.9) 1 1 (25.0)
Eye pain 0 0 2 2 (28.6) 0 0
Conjunctival hyperemia 2 1 (14.3) 0 0 0 0
Erythema of eyelid 1 1 (14.3) 0 0 0 0
Eye inflammation 0 0 1 1 (14.3) 0 0
Eye irritation 0 0 1 1 (14.3) 0 0
Foreign body sensation in eyes 0 0 0 0 1 1 (25.0)
Photophobia 0 0 1 1 (14.3) 0 0
General disorders and administration site conditions 1 1 (14.3) 3 2 (28.6) 0 0
Disease progressionx 1 1 (14.3) 0 0 0 0
Fatigue 0 0 1 1 (14.3) 0 0
Instillation site pruritus 0 0 1 1 (14.3) 0 0
Irritability 0 0 1 1 (14.3) 0 0
Nervous system disorders 0 0 2 2 (28.6) 0 0
Headache 0 0 2 2 (28.6) 0 0
Cardiac disorders 0 0 1 1 (14.3) 0 0
Cardiovascular disorderk 0 0 1 1 (14.3) 0 0
Musculoskeletal and connective tissue disorders 0 0 1 1 (14.3) 0 0
Muscle spasms 0 0 1 1 (14.3) 0 0
AE ¼ adverse event; max ¼ maximum; MedDRA ¼ Medical Dictionary for Regulatory Activities; min ¼ minimum; N/A: not available (ethnicity and race were not
collected in all countries); N ¼ number of patients randomized to each treatment group at baseline; NK ¼ neurotrophic keratitis/keratopathy; rhNGF ¼ recombinant
human nerve growth factor; SD ¼ standard deviation; TAE ¼ treatment-related adverse event.
Percentages (%) are calculated using the number randomized to each treatment group (N) as the denominator.
*Treatment-related AEs are those events recorded by the investigator as having a possible, probable, or highly probable relationship to study treatment.
yIncludes herpes simplex, herpes zoster, and recurrent herpetic keratitis.
zPatients may have received >1 prior treatment.
xDisease progression was defined as increase in lesion size 1 mm; decrease in best-corrected distance visual acuity by >5 Early Treatment Diabetic Retinopathy Study
letters; progression in lesion depth to corneal melting or perforation; or onset of infection. One patient in the rhNGF 10 mg/ml group had 1-mm increase in lesion
size from baseline.
kOne patient in the rhNGF 20 mg/ml group had a transient decrease in blood pressure from baseline.
Ophthalmology Volume -, Number -, Month 2018
2
Reports8 weeks, was well tolerated in patients with stage 2 or 3 NK. No
safety concerns arose; most AEs were ocular, mild, and transient,
and did not require discontinuing or corrective treatments. Most
patients had undetectable serum NGF, and systemic AEs were
infrequent and mild. This is consistent with previous PK findings in
healthy volunteers4 and lack of detectable systemic NGF or
immunogenicity in the phase II study.5 Taken together, these
results suggest unlikely systemic absorption or accumulation of
rhNGF. Favorable trends in corneal healing suggest that topical
ophthalmic rhNGF may be effective for treating patients with
moderate-to-severe NK.
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